Benjamin Brown, MD, University of Chicago
Objectives: To explore the prevalence of negative experiences with long-acting reversible contraception (LARC), shared by a friend or family member, and to assess the influence of these stories on decision-making. Methods: We performed a sub-study within a randomized controlled trial evaluating a contraceptive counseling intervention for women presenting for induced abortion (n=60). We surveyed participants ...Read more >
Corinne Rocca, PhD, MPH, University of California, San Francisco
Objectives: Expanding medication abortion to the pharmacy setting could help women access safe care. Studies have not evaluated pharmacy interventions. This non-inferiority study in Nepal investigated whether mifepristone-misoprostol medication abortion provided by trained nurses from pharmacies could be as effective and safe as when provided from government-certified abortion facilities. Methods: Nurses in two districts, Chitwan ...Read more >
Melissa Natavio, MD, MPH, University of Southern California
Objective: To determine if differences exist in the pharmacokinetics of levonorgestrel-only emergency contraception (LNG-EC) in normal, obese and extremely obese users. Methods: Healthy, reproductive-age, ovulatory women with normal (BMI 18.5-24.9 kg/m2), obese (BMI = 30-39.9 kg/m2) and extremely obese (BMI >= 40 kg/m2) BMIs were orally administered 1.5 mg LNG-EC. Dosing occurred on day 8 ...Read more >
Kathryn LaRoche, MSc, University of Ottawa
Background: After one of the longest drug review processes in Canadian history, in July 2015 Health Canada approved mifepristone/misoprostol, the gold-standard of medication abortion, for early pregnancy termination. However, Health Canada’s decision included a number of non-evidence based restrictions with respect to both gestational age eligibility and service delivery. Mifegymiso was finally introduced in early ...Read more >
Brittany Charlton, ScD, MSc, Boston Children's Hospital
The goal of our interdisciplinary project is to bring together researchers from three distinct fields—epidemiology, psychology, and medicine—to illuminate the experiences of sexual minorities who have had a teen pregnancy. We began a qualitative study with sexual minority women in Phase I of this grant, during which time we secured institutional review board approval, developed ...Read more >
Kate Grindlay, MSPH, Ibis Reproductive Health
California and Oregon were the first states in the US to expand the scope of pharmacist practice to include prescribing self-administered hormonal contraception under a statewide protocol. Both states implemented their pharmacist protocols in 2016. In California, wide-scale implementation of this law has been slow for a number of reasons, including that many retail pharmacy ...Read more >
Blair Darney, PhD, MPH, Oregon Health & Science University
Our formative work with abortion advocates revealed a need for more evidence about the safety of abortion, incidence of second trimester abortion, and the impact of the change in abortion law in Mexico City in 2007. Building on our current productive collaborations and responding to identified research needs, the goal of this proposal is to ...Read more >
Aileen Gariepy, MD, MPH, Yale University
Objectives: To develop and pilot test a mobile phone game intervention to decrease high risk sexual behavior (e.g. vaginal intercourse without condoms, multiple sexual partners, intercourse under the influence of drugs) in a group of 15-17 year-old Black and Latino adolescents. Methods: Iterative mixed methods design to create and develop a game prototype in waves ...Read more >
Erika Levi, MD, MPH, Albert Einstein College of Medicine
Immediate postpartum initiation of the etonogestrel contraceptive implant has been proven to decrease rates of rapid, repeat pregnancies. Evidence supports that in healthy women with term infants initiation of the contraceptive implant 1-3 days postpartum does not appear to have any adverse effects on lactogenesis or breastfeeding continuation. However, no high quality study to date ...Read more >
Sarah Roberts, DrPH, MPH, University of California, San Francisco
Objectives: To compare abortion-related morbidities and adverse events and costs from abortions provided at Ambulatory Surgery Centers (ASCs) versus office-based settings. Methods: Retrospective cohort study of 49287 women continuously enrolled in US private health insurance who had 50311 induced abortions in ASCs or office-based settings 2011 – 2014. Outcomes were ascertained during the six weeks ...Read more >